Loading peptide directory…
Side-by-side
Pick up to 3 peptides and see their key facts side by side. Useful for narrowing a search before deciding which page to read in full.
1 of 3 selected.
| Field | Last updated |
|---|---|
| Aliases | p53-penetratin chimera, PPLSQETFSDLWKLL-penetratin, p53(12-26)-membrane-residency peptide |
| Category | Other Research Peptides |
| Formula | — |
| Molecular weight | 4032 Da |
| Half-life | hours (preclinical) |
| Mechanism (summary) | PNC-27 is a 32-residue chimeric p53-derived anticancer peptide that fuses the p53 residues 12–26 HDM-2-binding domain (PPLSQETFSDLWKLL) to a membrane-penetrating / membrane-residency sequence. It selectively binds HDM-2/MDM2 expressed on cancer-cell membranes, induces transmembrane pore formation, and causes necrotic lysis. No human clinical dataset was identified in the source material. |
| Dosing notes | No validated human dose. The most cited animal regimen is 40 mg/kg intraperitoneally once daily for 2 weeks in leukemic mouse models. Dose translation to humans is not established. |
| Storage |
|---|
No authoritative clinical product monograph or standardized stability data were identified. Vendor-specific reconstitution rules should be treated as supplier-specific, not authoritative. |
| Read more | Full reference → |
|---|